Incidence, severity, and predictors of early postoperative dry eye disease following femtosecond laser-assisted in situ keratomileusis (FS-LASIK): a short-term, single-center retrospective analysis

Evidence database / Studies / wu-2026-fs-lasik-early-dry-eye

3,000enrolled patients*

—enrolled eyes*

1structured arms

90maximum standardized days follow-up

* Descriptive sum of reported arm counts. “≥” indicates that one or more arm counts were not reported; missing values are not treated as zero.

Study arm

FS-LASIK cohort

LASIK

Population

Patients: 3000
Eyes: Not reported
Bilateral treatment: Not reported
Age range: Not reported
Sphere range: Not reported
Cylinder range: Not reported
Spherical equivalent: Not reported
Corneal thickness: Not reported

Eligibility definition

Inclusion
Patients who underwent FS-LASIK between January 2020 and December 2024.

Exclusion
Not structured

Reported outcomes by follow-up

Outcome	Follow-up	Follow-up sample	Result	Reported fraction	Provenance
Dry eye symptoms (OSDI ≥13) symptoms	1 week	3000 patients	25.0%	denominator: 3000 patients	VERIFIED Source · Abstract
Dry eye symptoms (OSDI ≥13) symptoms	1 month	3000 patients	38.0%	denominator: 3000 patients	VERIFIED Source · Abstract
Dry eye symptoms (OSDI ≥13) symptoms	3 months	3000 patients	15.0%	denominator: 3000 patients	VERIFIED Source · Abstract

Complications

No structured complication observations are available for this arm. This means “not reported in this dataset,” not zero complications.

Study design

Single-center retrospective analysis of patients undergoing FS-LASIK from January 2020 through December 2024, with dry eye defined as OSDI score 13 or higher.

Country: China
Publication-reported places: Longyan First Affiliated Hospital of Fujian Medical University, Fujian, China
Multicenter: No
Prospective: No
Randomized: No
Source type: RETROSPECTIVE
Regulator: Not reported

Place metadata may refer to a treatment site, institution or author affiliation. Confirm its role in the linked publication.

Limitations and notes

The abstract reports early patient-level symptom rates through three months. It does not establish long-term persistence.

Missing fields are not interpreted as negative findings. Arm counts may not be additive in all study designs.

Study evidence level
A simple, non-GRADE hierarchy based on design: randomized and large regulatory trials are high; prospective cohorts moderate; retrospective observational studies low. Manual review can override this label.